<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
placeholder

Dr. Bunn on Data With Trastuzumab Deruxtecan in HER2-Mutant NSCLC

Default sub title

minute read

Written by OncLive on July 27, 2020

Paul A. Bunn, Jr, distinguished professor, James Dudley Chair in Lung Cancer Research, Division of Medical Oncology, University of Colorado and a 2014 Giant of Cancer Care® in Lung Cancer, highlights encouraging data with fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-mutant non–small cell lung cancer (NSCLC).

Comments

Related Stories